STIM Neuronetics, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1227636 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY23.0%
TTM net income YoY48.1%
TTM EPS YoY61.4%
Revenue 3-yr CAGR32.1%
Net income 3-yr CAGR—
Margins
Gross margin50.7%
Operating margin-9.4%
Net margin-14.4%
FCF margin-6.0%
EBITDA margin-8.0%
Returns
ROE-100.2%
ROA-16.6%
ROIC (approx.)-19.2%
Asset turnover1.15x
Leverage & solvency
Liabilities / assets83.0%
Debt / equity3.30x
Current ratio2.01x
Interest coverage-1.69x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-10.7%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $149.16M | $74.89M | $71.35M | $65.21M | $55.31M |
| Cost of revenue | $76.85M | $20.73M | $19.64M | $15.48M | $11.65M |
| Gross profit | $72.31M | $54.16M | $51.70M | $49.72M | $43.66M |
| R&D expense | $6.58M | $12.77M | $9.52M | $9.34M | $7.92M |
| SG&A expense | $49.70M | $30.32M | $25.43M | $25.52M | $25.55M |
| Operating income | -$31.44M | -$34.56M | -$30.55M | -$35.11M | -$27.56M |
| Interest expense | $8.41M | $7.29M | $5.42M | $4.25M | $4.02M |
| Net income | -$39.00M | -$43.71M | -$30.19M | -$37.16M | -$31.19M |
| EBITDA | -$27.97M | -$32.49M | -$28.55M | -$33.46M | -$26.50M |
| EPS (basic) | -0.59 | -1.38 | -1.05 | -1.38 | -1.22 |
| EPS (diluted) | -0.59 | -1.38 | -1.05 | -1.38 | -1.22 |
| Weighted avg. shares (diluted) | 65.95M | 31.73M | 28.66M | 26.90M | 25.48M |
| Balance sheet | |||||
| Cash & equivalents | $28.13M | $19.46M | $59.68M | $70.34M | $94.14M |
| Receivables | $16.47M | $23.36M | $15.78M | $13.59M | $7.71M |
| Inventory | $4.33M | $4.25M | $8.09M | $8.90M | $6.56M |
| Current assets | $61.55M | $58.12M | $93.79M | $98.77M | $115.33M |
| PP&E, net | $4.47M | $6.24M | $2.01M | $1.99M | $1.22M |
| Goodwill | $23.62M | $18.63M | — | — | — |
| Intangibles | $18.15M | $19.61M | — | — | — |
| Total assets | $141.55M | $140.90M | $115.83M | $116.88M | $141.22M |
| Current liabilities | $30.52M | $31.27M | $19.81M | $33.20M | $15.70M |
| Short-term debt | — | — | — | $13.12M | — |
| Long-term debt | $65.81M | $55.15M | $59.28M | $22.83M | $35.34M |
| Total debt | $65.81M | $55.15M | $59.28M | $35.95M | $35.34M |
| Total liabilities | $115.31M | $109.10M | $81.64M | $59.82M | $56.05M |
| Shareholders' equity | $22.38M | $27.71M | $34.19M | $57.06M | $85.17M |
| Net debt | $37.67M | $35.69M | -$394,000 | -$34.39M | -$58.81M |
| Shares outstanding | 68.99M | 55.68M | 29.09M | 27.27M | 26.39M |
| Cash flow statement | |||||
| Operating cash flow | -$20.37M | -$31.00M | -$32.04M | -$30.74M | -$27.98M |
| Capital expenditure | $801,000 | $1.47M | $2.37M | $3.27M | $2.35M |
| Free cash flow | -$21.18M | -$32.46M | -$34.41M | -$34.01M | -$30.34M |
| Investing cash flow | -$801,000 | -$2.41M | -$1.32M | $6.73M | -$9.84M |
| Financing cash flow | $35.85M | -$6.81M | $22.70M | $207,000 | $83.01M |
| Depreciation & amortization | $3.46M | $2.07M | $2.01M | $1.65M | $1.06M |
| Stock-based compensation | $6.85M | $5.60M | $7.32M | $8.75M | $7.87M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.